AIMIL sold BGR-34 as a diabetes cure with no proof; ASCI banned it as unlawful

In 2016, BGR-34 - an ayurvedic anti-diabetes capsule developed by two Lucknow-based CSIR laboratories, NBRI and CIMAP, and manufactured and marketed by private firm AIMIL Pharmaceuticals - was being promoted with a striking claim: it cures type 2 diabetes mellitus without any side effects. The marketing touted 34 phyto-constituents that 'convert proinsulin to insulin', and the brand won an AYUSH brand-of-the-year award in 2016. Doctors were unconvinced: the Indian Medical Association's Maharashtra leadership publicly questioned the drug's effectiveness.

The evidence base was thin. CIMAP's own director described a single clinical trial: four months, 56 patients, one Delhi hospital. An NBRI scientist cited a '67% success' figure. Alt News checked PubMed and Google Scholar in July 2017 and found no published human-trial data at all; the one CTRI-registered trial (November 2016) reported no pharmacokinetic data and summarised its outcome merely as 'promising'. A Pune University professor noted the labs had no BGR-34 paper in any reputed journal and no registered trial records.

In 2017, ASCI's Consumer Complaints Council upheld a complaint against the ads: the cure-without-side-effects claim was unsubstantiated and misleading - and, as a cure claim for a disease, it breached the Drugs & Magic Remedies Act, which outlaws exactly that kind of advertising. BGR-34 landed in ASCI's July 2017 list of 134 banned ads alongside a row of ayurvedic 'miracle' advertisers promising cancer cures and no-operation kidney stone treatment.

Ads banned; ASCI held the cure claim breached the Drugs & Magic Remedies Act. Doctors' bodies and fact-checkers publicly dismantled the drug's evidence.

The core efficacy claim rested on one small, unpublished, single-hospital trial - nothing a regulator, doctor or journalist could verify.

'Cure' language for a lifelong disease crossed from puffery into the Drugs & Magic Remedies Act's statutory prohibition.

The developers' institutional pedigree created a halo: the brand traded on publicly funded labs' credibility that its evidence never matched.

Regulators and medical associations were already primed against miracle-cure advertising; BGR-34 handed them a flagship target.

Scientific pedigree is not evidence. Marketing a drug ahead of published trials turns every ad into legal liability, and 'cure' claims for chronic disease draw the harshest scrutiny of all.

The ban did not kill the product: BGR-34 stayed on the market, and its developers kept defending it. But the scrutiny stuck: the ruling filed a publicly funded research brand in the same list as unlicensed 'miracle' clinics, the IMA's criticism stayed on record, and Alt News's fact-check still sits next to AIMIL's marketing in search results. The companion drug AYUSH-82's promotional video, fronted by a senior research-council official, was withdrawn in 2016 after four months, a former AYUSH secretary accusing the council of creating 'a false sense of security' among patients.